Evidence map›Paper›PMID 30121892›Full record

Trial reportInternational journal of hematology2018

A phase 3b, multicenter, open-label extension study of the long-term safety of anagrelide in Japanese adults with essential thrombocythemia.

Yuzuru Kanakura, Yukari Shirasugi, Hiroki Yamaguchi, Michiaki Koike, Takaaki Chou, Shinichiro Okamoto, Heinrich Achenbach, Jingyang Wu, Chiaki Nakaseko

Registry-linked trialAbstract readClinical Trial, Phase IIIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01467661 (A Phase 3, Multi-centre, Open-label, Extension Study to Investigate the Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01467661 phase3completednot on this map

A Phase 3, Multi-centre, Open-label, Extension Study to Investigate the Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia

TypeinterventionalSponsorShireRan2010 to 2015Enrolled41ConditionsEssential Thrombocythemia (ET)ArmsSPD422 (anagrelide hydrochloride)
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 2 countries.

Yuzuru KanakuraGraduate School of Medicine, Osaka University, Osaka University Hospital, C9, 2-2, Yamada-oka, Suita, Osaka, 565-0871, Japan. kanakura@bldon.med.osaka-u.ac.jp.
Yukari ShirasugiTokai University School of Medicine, Isehara, Japan.
Hiroki YamaguchiDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Michiaki KoikeJuntendo University Shizuoka Hospital, Shizuoka, Japan.
Takaaki ChouNiigata Cancer Center Hospital, Niigata, Japan.
Shinichiro OkamotoKeio University Hospital, Tokyo, Japan.
Heinrich AchenbachResearch & Development, Shire GmbH, Zug, Switzerland.
Jingyang WuGlobal Biometrics, Shire Pharmaceuticals, Lexington, MA, USA.
Chiaki NakasekoChiba University Hospital, Chiba, Japan.
Chiba University Hospital · JPJuntendo University Shizuoka Hospital · JPKeio University Hospital · JPNiigata Cancer Center Hospital · JPNippon Medical School · JPOsaka University Hospital · JPTakeda (United States) · USTokai University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytoreductive therapy is used in high-risk essential thrombocythemia (ET) to reduce risk of thrombohemorrhagic complications. Anagrelide is an orally active, quinazolone-derived platelet-lowering agent approved for first-line treatment of high-risk ET in Japan. Long-term safety and efficacy data were collected from 53 Japanese high-risk ET patients (Study 308); 41 patients who completed Study 308 entered this phase 3b, open-label extension (Study 309; NCT01467661). Reductions in mean platelet counts occurred throughout the study, from 1021.6 × 10

Indexed as

AdultAgedAged, 80 and overFemaleHumansJapanMaleMiddle AgedPlatelet CountQuinazolinesRisk FactorsThrombocythemia, EssentialTime FactorsanagrelideQuinazolinesAnagrelideEssential thrombocythemiaJapan

Identifiers

PMID30121892
OpenAlexW2886333064

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.